Fibrates or statins and lipid plasma levels in 245 patients treated with highly active antiretroviral therapy. Aquitaine cohort, France, 1999-2001

HIV Medicine

Volumn 5, Issue 3, 2004, Pages 133-139

  Bonnet, Fabrice ^a,b   Balestre, E ^b   Thiebaut R ^b   Mercie P ^a   Dupon, M ^c   Morlat, P ^a,b   Dabis, F ^b  

^a BORDEAUX UNIVERSITY HOSPITAL   (France)

^b INSERM   (France)

^c University Hospital   (France)

Author keywords

Cholesterol; Fibrate; Highly active antiretroviral therapy; HIV; Statin; Triglycerides

Indexed keywords

ANTIRETROVIRUS AGENT; ATORVASTATIN; BEZAFIBRATE; CD4 ANTIGEN; CHOLESTEROL; CIPROFIBRATE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; LIVER ENZYME; MUSCLE ENZYME; PRAVASTATIN; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SIMVASTATIN; TRIACYLGLYCEROL;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG TOLERABILITY; DYSLIPIDEMIA; FEMALE; FRANCE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIPID BLOOD LEVEL; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSPECTIVE STUDY; T LYMPHOCYTE; TRIACYLGLYCEROL BLOOD LEVEL; VIRUS LOAD;

ADULT; ANTILIPEMIC AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CHOLESTEROL; COHORT STUDIES; FEMALE; HIV INFECTIONS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; LIPIDS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; TRIGLYCERIDES;

EID: 2942674447     PISSN: 14642662     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2004.00200.x     Document Type: Article

References (29)

1. Periard D, Telenti A, Sudre P et al. Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. The Swiss HIV Cohort Study. Circulation 1999; 100: 700-705.
2. Thiébaut R, Dabis F, Malvy D et al. Serum triglycerides, HIV infection, and highly active antiretroviral therapy, Aquitaine Cohort, France, 1996-98. Groupe d'Epidemiologie Clinique du Sida en Aquitaine (GECSA). J Acquir Immune Defic Syndr 2000; 23: 261-265.
3. Bonnet F, Savès M, Droz C et al. Increase of atherogenic plasma profile in HIV-infected patients treated with protease inhibitor-containing regimens. J Acquir Immune Defic Syndr 2000; 25: 199-200.
4. Friis-Moller N, Weber R, Reiss P et al. Cardiovascular disease risk factors in HIV patients - association with antiretroviral therapy. Results from the DAD study. AIDS 2003; 23: 1179-1193.
5. Mary-Krause M, Cotte L, Simon A, Partisani M, Costagliola D and the Clinical Epidemiology Group from the French Hospital Database. Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men. AIDS 2003; 17: 2479-2486.
6. The Data Collection on Adverse Events of Anti-HIV Drugs (DAD) Study Group. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 2003; 349: 1993-2003.
7. Ruiz NM, Bessen LJ, Manion DJ et al. Potential adverse experiences associated with efavirenz in adults. Sixth Conference on Retroviruses and Opportunistic Infection. Chicago, IL. February 2001 [Abstract 655].
8. Bonnet F, Bonarek M, deWitte S, Beylot J, Morlat P. Efavirenz-associated severe hyperlipidemia. Clin Infect Dis 2002; 35: 776-777.
9. Bonnet F, Lawson-Ayayi S, Thiébaut R et al. Tolerance and efficacy of nevirapine-containing regimens: a retrospective study of 137 patients Aquitaine cohort 1997-99. Clin Infect Dis 2002; 35: 1231-1237.
10. Van Leth F, Phanuphak P, Gazzard B et al. Lipid changes in a randomized comparative trial of first-line antiretroviral therapy with regimens containing either nevirapine alone, efavirenz alone or both drugs combined, together with stavudine and lamivudine (2NN Study). Tenth Conference on Retroviruses and Opportunistic Infection. Boston, MA, February 2003 [Abstract 752].
11. Doser N, Sudre P, Telenti A et al. Persistent dyslipidemia in HIV-infected individuals switched from a protease inhibitor-containing to an efavirenz-containing regimen. J Acquir Immune Defic Syndr 2001; 26: 389-390.
12. Martinez E, Conget I, Lozano L, Casamitjana R, Gatell JM. Reversion of metabolic abnormalities after switching from HIV-1 protease inhibitors to nevirapine. AIDS 1999; 13: 805-810.
13. Fichtenbaum CJ, Gerber JG, Rosenkranz SL et al. Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047. AIDS 2002; 16: 569-577.
14. Marimoutou C, Chêne G, Dabis F, Lacoste D, Salamon R. Human immunodeficiency virus infection and AIDS in Aquitaine. 10 years' experience of a hospital information system, 1985-95. Le Groupe d'Epidémiologie Clinique du SIDA en Aquitaine (GECSA). Presse Med 1997; 26: 703-710 (in French).
15. Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). J Am Med Assoc 2001; 285: 2486-2497.
16. Anonymous. National Cholesterol Education Program: second report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Circulation 1994; 89: 1329-1445.
17. Recommandations du Groupe d'Expert. Complications des Traitements Antirétroviraux. Prise en Charge des Personnes Infectées par le VIH. Rapport 2002. Paris, France, Medecine-Sciences Flammarion 2002: 117-130.
18. Hokanson JE, Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk 1996; 3: 213-219.
19. Eberly LE, Stamler J, Neaton JD. Relation of triglyceride levels, fasting and nonfasting, to fatal and nonfatal coronary heart disease. Arch Intern Med 2003; 163: 1077-1083.
20. Rubins HB, Robins SJ, Collins D et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 1999; 341: 410-418.
21. Henry K, Melroe H, Huebesch J, Hermundson J, Simpson J. Atorvastatin and gemfibrozil for protease-inhibitor-related lipid abnormalities. Lancet 1998; 352: 1031-1032.
22. Hewitt RG, Shelton MJ, Esch LD. Gemfibrozil effectively lowers protease inhibitor-associated hypertriglyceridemia in HIV-1 positive patients. AIDS 1999; 13: 868-869.
23. Miller J, Carr A, Brown D et al. A randomised, double-blind study of gemfibrozil for the treatment of protease inhibitor-associted hypertriglyceridemia. Seventh Conference on Retroviruses and Opportunistic Infection. San Francisco, CA, February 2001 [Abstract 540].
24. Calza L, Manfredi R, Chiodo F. Statins and fibrates for the treatment of hyperlipidemia in HIV-infected patients receiving HAART. AIDS 2003; 17: 851-859.
25. Manninen V, Tenkanen L, Koskinen P et al. Joint effects of serum triglycerides and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study: implication for treatment. Circulation 1992; 85: 37-45.
26. West of Scotland Coronary Prevention Study Group. Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS). Circulation 1998; 97: 1440-1445.
27. Neuvonen PJ, Kantola T, Kivisto KT. Sinvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole. Clin Pharmacol Ther 1998; 63: 332-341.
28. Moyle GM, Lloyd M, Reynolds B et al. Dietary advice with or without pravastatin for the management of hypercholesterolemia associated with protease inhibitor therapy. AIDS 2001; 15: 1503-1508.
29. Murillas J, Martin T, Ramos A, Portero JL. Atorvastatin for protease inhibitor-related hyperlipidaemia. AIDS 1999; 13: 1424-1425.